uploads/2018/06/computer-3343887_1280.jpg

How Much Upside Do Analysts See in Baxter Stock?

By

Updated

Company overview

Baxter International (BAX) provides a broad portfolio of essential healthcare products. Its products include acute and chronic dialysis, intravenous solutions, infusion systems, inhaled anesthetics, injectable pharmaceuticals, surgical hemostats, and sealants. Baxter has a global presence with manufactured products in more than 20 countries and sales in more than 100 countries.

Analysts’ recommendations

Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating. Six have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.3 with a target price of $78.33, implying an upside potential of 4.1% over the stock’s closing price of $75.28 on June 5.

Peer ratings

In June, 16 of the 20 analysts covering Abbott Laboratories (ABT) gave the stock a “buy” or higher rating. Four of them gave given it a “hold.” The mean rating for the stock is 1.9 with a target price of $68.56.

Of the 19 analysts covering Becton Dickinson (BDX) in June, 13 of them have given the stock a “buy” or higher rating, and six have given it a “hold.” The mean rating for the stock is 1.9 with a target price of $252.65.

Of the 24 analysts covering Boston Scientific (BSX) in June, 19 of them have given the stock a “buy” or higher rating, and five have given it a “hold.” The mean rating for the stock is 1.7 with a target price of $32.76.

In the next part of this series, we’ll take a look at Baxter International’s geographic segments.

More From Market Realist